Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?

Published

Journal Article

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in ≤50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme.

Full Text

Duke Authors

Cited Authors

  • Ok, CY; Ye, Q; Li, L; Manyam, GC; Deng, L; Goswami, RR; Wang, X; Montes-Moreno, S; Visco, C; Tzankov, A; Dybkaer, K; Zhang, L; Abramson, J; Sohani, AR; Chiu, A; Orazi, A; Zu, Y; Bhagat, G; Richards, KL; Hsi, ED; Choi, WWL; van Krieken, JH; Huh, J; Ponzoni, M; Ferreri, AJM; Zhang, S; Parsons, BM; Xu, M; Møller, MB; Winter, JN; Piris, MA; Xu-Monette, ZY; Medeiros, LJ; Young, KH

Published Date

  • June 2015

Published In

Volume / Issue

  • 6 / 16

Start / End Page

  • 13933 - 13945

PubMed ID

  • 26101854

Pubmed Central ID

  • 26101854

Electronic International Standard Serial Number (EISSN)

  • 1949-2553

International Standard Serial Number (ISSN)

  • 1949-2553

Digital Object Identifier (DOI)

  • 10.18632/oncotarget.4324

Language

  • eng